Skip to content

Mapping the hepatitis C cascade of care in people attending drug treatment services in England: A data linkage study

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)55 - 60
Number of pages6
JournalInternational Journal of Drug Policy
Early online date27 Jun 2019
DateAccepted/In press - 1 Jun 2019
DateE-pub ahead of print - 27 Jun 2019
DatePublished (current) - 1 Oct 2019


Introduction: Hepatitis C (HCV) infection in England primarily affects people who inject drugs (PWID). We describe persons HCV tested, estimate incidence and establish the cascade of care (CoC) for people engaging with drug services.

Methods: Persons testing for HCV in drug services in Sentinel Surveillance of Blood Borne Virus Testing (SSBBV) between 2008 and 2016 were linked with people attending drug services in the National Drug and Treatment Monitoring System (NDTMS). We describe risk characteristics, establish the CoC, and estimate HCV incidence in PWID diagnosed in drug services. 

Results: Of 46,721 persons tested for anti-HCV in SSBBV in drug services, 29,773 (63.7%) linked to NDTMS. Of these, 9100 (30.6%) were antiV positive and anti-HCV positivity was 45.0% in persons reporting urgent housing problems and 43.8% in persons reporting ever injecting. Among persons anti-HCV positive, half had ≥1 positive anti-HCV test. For persons’ first anti-HCV positive between 2008 and 2013 (n = 3123), 74.9% were HCV RNA tested, of whom 71.2% were RNA positive, and of these, 14.0% had evidence of interferon-based treatment, with 52.8% achieving cure. Among PWID, HCV incidence was 8.7 per 100 person-years (95% CI: 8.1–9.2). 

Conclusion: Through record linkage of surveillance datasets, we estimated the HCV CoC for people attending drug services, providing a benchmark from which to monitor the impact of strategies to scale-up prevention, testing, and curative treatment with direct acting antivirals. Our study highlights wasteful repeated testing and poor linkage to care for this high risk population which need to be addressed.

Additional information

The acceptance date for this record is provisional and based upon the month of publication for the article.

    Research areas

  • Cascade of care, Hepatitis C, People who inject drugs, Treatment



  • Full-text PDF (author’s accepted manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at . Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 318 KB, PDF document

    Embargo ends: 27/06/20

    Request copy

    Licence: CC BY-NC-ND


View research connections

Related faculties, schools or groups